GLP-1 drugs and erectile dysfunction

A meta-analysis published in the World Journal of Methodology on 20 September 2026 pooled seven small studies of GLP-1 receptor agonists and found that treatment was associated with an improvement in erectile dysfunction (ED) scores, not a worsening of them^[1]. That finding sits awkwardly next to a separate, larger real-world study published in 2024 that found semaglutide prescriptions were associated with a much higher rate of new ED diagnoses in young obese men^[2]. Both papers are real, peer-reviewed, and measuring different things in different populations. Neither settles the question, and this article explains why.

What the new meta-analysis found

The authors, based at the University of Tabuk in Saudi Arabia, searched PubMed, Google Scholar and Web of Science for studies examining GLP-1 receptor agonists (the drug class that includes semaglutide, liraglutide, dulaglutide and the dual GIP/GLP-1 agonist tirzepatide) and erectile function. Seven studies met their criteria, covering 237 men in total^[1]. Pooled together, GLP-1 agonist therapy was associated with a statistically significant improvement in ED score, a mean difference of 2.73 points on a validated scale (95% confidence interval: 1.64 to 3.83).

The same pooled data showed increases in total testosterone (mean difference 73.04 ng/dL), sex hormone binding globulin (mean difference 7.00), and follicle-stimulating hormone (mean difference 0.46), with no significant change in free testosterone or luteinizing hormone^[1]. The authors' own conclusion is measured: GLP-1 agonists significantly improved ED, total testosterone, SHBG and FSH in the pooled sample, and larger randomized trials are needed before that finding can be treated as settled.

A conflicting signal from a much larger database

A 2024 study using the TriNetX real-world health records database looked at the same drug class from the opposite direction and reached a different answer^[2]. Researchers matched 3,094 pairs of non-diabetic obese men aged 18 to 50, average BMI 38.6, who were and were not prescribed semaglutide for weight loss, then compared new ED diagnosis rates. Men prescribed semaglutide were diagnosed with ED at 1.47%, versus 0.32% in the matched comparison group, a relative risk of 4.5 (95% CI: 2.3 to 9.0). The same cohort also showed a higher rate of new testosterone-deficiency diagnoses (relative risk 1.9).

These are not small effect sizes, and this is not a fringe journal. Any honest account of the evidence has to hold both studies at once rather than picking the one that fits a preferred narrative.

Why two credible studies can point in opposite directions

Part of the answer is what each study actually measured. The meta-analysis pooled small clinical studies, several of which enrolled men with obesity or type-2 diabetes and tracked change over time on structured ED scoring instruments, alongside hormone panels. The TriNetX study pulled new-diagnosis billing codes from electronic health records for a much younger, uniformly obese cohort prescribed semaglutide specifically for weight loss, not diabetes. A diagnosis code in a database can reflect a new symptom, but it can also reflect a patient who is now seeing a doctor more often during a structured weight-loss program and getting screened for something that was already present but unrecorded.

There is also a well-established, unrelated mechanism that can explain the meta-analysis's positive finding without invoking anything specific to the GLP-1 receptor itself. A 2026 JAMA review of adult male hypogonadism notes that obesity-related secondary hypogonadism affects roughly 2% to 8% of men, that weight loss is the recommended first-line treatment for it, and that weight loss of at least 5% typically raises total testosterone and improves erectile function on its own^[3]. Every GLP-1 drug in the pooled meta-analysis produces meaningful weight loss. It would not be surprising if hormonal and erectile-function improvement tracked the weight loss rather than any direct action of the drug on sexual function.

What is not established yet

The meta-analysis itself is small, seven studies and 237 men, and the authors say so directly: larger randomized trials are needed^[1]. It also pooled genuinely different drugs (semaglutide, liraglutide, dulaglutide, tirzepatide) and, by the authors' own description, different underlying study populations, which makes the single pooled number less precise than it looks. Current manufacturer prescribing information reflects this uncertainty: the Mounjaro (tirzepatide) label lists nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain as the most common adverse reactions, and does not currently list erectile dysfunction or sexual dysfunction as an adverse event^[4]. That is a snapshot of the label as written, not proof that no effect exists either way. Regulatory labeling updates lag the research literature by design; it takes accumulated postmarketing surveillance data before an agency will add a new warning.

If you are on a GLP-1 medication and notice a change in erectile function, in either direction, the useful move is to tell your prescriber rather than to self-diagnose from a headline. They can check whether the change tracks your weight loss, your other medications, or something separate that deserves its own workup.

Practical context

For now, the honest summary is that the evidence on GLP-1 agonists and erectile function is mixed and still forming. One small meta-analysis found average improvement alongside hormonal gains. One larger real-world database study found a sharply elevated rate of new ED diagnoses in a younger, weight-loss-specific population. See our semaglutide and tirzepatide pages for the fuller safety and regulatory picture on each drug, and talk to a clinician who knows your history before drawing conclusions about your own body from either study.